SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment

Core Insights - SINTX Technologies has signed a Joint Development Agreement (JDA) with NED Medical Inc. to develop advanced ceramic-based microspheres for radiotherapeutic applications [1][2] - The collaboration aims to transition the microsphere process from R&D to pilot production, focusing on preclinical testing and regulatory submissions [2][4] Group 1: Partnership Details - The partnership will leverage SINTX's ceramic manufacturing expertise to support NED Medical's preclinical testing and process validation [2] - SINTX has successfully manufactured ceramic-based microspheres containing Yttrium-90 that meet NED Medical's specifications for a TARE device targeting hepatocellular carcinoma [2][3] - The engineered microspheres feature porosity, allowing for future adaptations in targeted chemotherapy and combination therapies [2] Group 2: Strategic Implications - This partnership signifies SINTX's strategic expansion into the high-growth field of radio therapeutics, a market expected to grow significantly in the coming years [4] - SINTX's proprietary ceramic microsphere technology is anticipated to optimize dosing and enhance treatment precision, positioning the company as a leader in targeted radio-therapeutic devices [4][5] - The agreement opens avenues for future collaborations, including scaling production and expanding indications within oncology and musculoskeletal areas [4] Group 3: Leadership and Innovation - The partnership is expected to transform cancer treatment and underscores SINTX's commitment to advancing innovative solutions in oncological therapies [3] - Dr. Ryan Bock, CTO of SINTX, will join NED Medical's Scientific Advisory Board to guide the clinical development of CombiSphere [3]